An exploratory study investigating Pexastimogene-devacirepvec in combination with ipilimumab in patients with advanced melanoma
Phase of Trial: Phase II
Latest Information Update: 05 Sep 2016
At a glance
- Drugs Ipilimumab (Primary) ; Pexastimogene devacirepvec (Primary)
- Indications Malignant melanoma; Solid tumours
- Focus Therapeutic Use
- 05 Sep 2016 According to a Transgene media release, the company expects the first data readout in 2017.
- 05 Sep 2016 According to a Transgene media release, this trial is expected to initiate in the second half of 2016.
- 19 Nov 2015 New trial record